The program targets adults who meet medical criteria for GLP-1 medications, typically those with a BMI of 30 or higher or 27+ with weight-related health conditions, and who want more support than a prescription alone
(2000) Heffernan, Jiang, Thorburn, and Ng evaluated the metabolic effects of orally administered AOD-9604 in rodent models and the lipolytic activity of the compound on isolated human adipose tissue ex vivo
Similarly, the Wegovy Savings Program offers discounts or introductory pricing that help patients begin treatment without relying on compounded substitutes
Look at BMI along with waist size, activity level, and body composition when possible [22]
Nevertheless, when symptoms correlate closely with treatment initiation or dose changes, medication involvement becomes more likely
Recognising these symptoms is crucial for appropriate management, particularly when taking any new medication